P-319Long term efficacy results from the phase II CRAB trial: Neoadjuvant bevacizumab, capecitabine and radiotherapy in locally advanced rectal cancer

Introduction: Neoadjuvant capecitabine based chemoradiotherapy and radical surgery are considered to be optimal treatment approach to locally-advanced rectal cancer This prospective, nonrandomised, open -label phase II study investigated the efficacy and safety of bevacizumab (Bev) in combination with capecitabine and concurrent radiotherapy (CRT) for the treatment of locally advanced resectable rectal cancer (LARC). The pathological complete response (pCR) was assessed as primary endpoint and local control and survival parameters as secondary endpoints.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research